Drugs / IKT-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07632898 | Oct 2026 → Jun 2030 expected | pulmonary arterial hypertension | Inhibikase Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07365332 | Apr 2026 → Jun 2029 expected | pulmonary arterial hypertension | Inhibikase Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-07-23 | Inhibikase Therapeutics | Regulatory Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH inhibikase.com ↗
today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-23 | Inhibikase Therapeutics | Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH inhibikase.com ↗ |
| 2026-04-07 | Inhibikase Therapeutics | Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension inhibikase.com ↗ |
| 2025-11-20 | Inhibikase Therapeutics | Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension inhibikase.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IKT-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07365332 ↗ |
| Route | Oral | “IKT-001 tablets for PO administration” NCT07365332 ↗ |